Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: Where are we now? Where are we going?

Future Medicinal Chemistry

Volumn 3, Issue 7, 2011, Pages 855-879

  Antonovic, Leposava ^a   Martinez, Marilyn ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; ERYTHROMYCIN; ISOFLURANE; KETAMINE; MEDETOMIDINE; MONENSIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PARACETAMOL; PHENOBARBITAL; PROPOFOL; SALINOMYCIN; TIAMULIN; UNINDEXED DRUG; VETERINARY DRUG;

AGE; ANIMAL HEALTH; BIRTH; BLOOD; BRAIN; BREEDING; CARCINOGENESIS; CAT; CATTLE; CHICKEN; CHROMOSOME; CIRCADIAN RHYTHM; COMPUTER MODEL; COW; DEALKYLATION; DOG; DRUG EXPOSURE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME MODIFICATION; EPIGENETICS; ETHNIC GROUP; EXPERIMENTAL MODEL; GENDER; GENE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENERAL ASPECTS OF DISEASE; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GOLGI COMPLEX; HORSE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYDROXYLATION; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY; KIDNEY CLEARANCE; LIPOPHILICITY; LIVER; LUNG; MATURATION; METABOLISM; MICROSOME; MINIPIG; MOLECULAR BIOLOGY; NEUTROPHIL; NONHUMAN; OXIDATION; PHARMACOGENETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; POULTRY; PRIORITY JOURNAL; RABBIT; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SAFETY; SEMINAL VESICLE; SEQUENCE HOMOLOGY; SMALL INTESTINE; SOLUBILITY; SULFATION; SWINE; TARGET ANIMAL SAFETY; THROMBOCYTE; THROMBOSIS; TOXICITY; ULTRACENTRIFUGATION; VETERINARY MEDICINE;

ANIMALS; CATS; CATTLE; CHICKENS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; ENZYME INHIBITORS; PROTEIN ISOFORMS; RATS; SWINE; VETERINARY DRUGS;

EID: 79958764153     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.37     Document Type: Review

References (98)

1. US FDA Guidance for Industry. Target Animal Safety for Veterinary Pharmaceutical Products, VICH GL43 (2010)
2. Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 3(5), 481-490 (2002). (Pubitemid 34987481)
3. Sallustio BC, Sabordo L, Evans AM, Nation RL. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1(2), 163-180 (2000).
4. Glatt H. Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J. 11(5), 314-321 (1997). (Pubitemid 27193935)
5. Coleman M. Human Drug Metabolism: An Introduction. John Wiley & Sons Ltd, NY, USA (2005).
6. Brodie BB, Gillette JR, La Du BN. Enzymatic metabolism of drugs and other foreign compounds. Annu. Rev. Biochem. 27(3), 427-454 (1958).
7. Omura T, Sato R. A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375-1376 (1962).
8. Omura T. Structural diversity of cytochrome P450 enzyme system. J. Biochem. 147(3), 297-306 (2010).
9. Neve EP, Ingelman-Sundberg M. Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. Curr. Opin. Drug Discov. Devel. 13(1), 78-85 (2010).
10. Ioannides C. Cytochrome p450 expression in the liver of food-producing animals. Curr. Drug Metab. 7(4), 335-348 (2006).
11. Graham MJ, Lake BG. Induction of drug metabolism: species differences and toxicological relevance. Toxicology 254(3), 184-191 (2008).
12. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug Metab. 7(2), 165-182 (2006).
13. Nelson DR. The cytochrome p450 homepage. Hum. Genomics 4(1), 59-65 (2009).
14. Eddy SR. A new generation of homology search tools based on probabilistic inference. Genome Inform. 23(1), 205-211 (2009).
15. Ortiz de Montellano PR. Cytochrome P450: Structure, Mechanism, and Biochemistry. Kluwer Academic/Plenum Publishers, NY, USA (2005)
16. Larhammar D, Sundstrom G, Dreborg S, Daza DO, Larsson TA. Major genomic events and their consequences for vertebrate evolution and endocrinology. Ann. NY Acad. Sci. 1163, 201-208 (2009).
17. Nebbia C, Dacasto M, Rossetto GA, Giuliano AA, Carletti M. Comparative expression of liver cytochrome P450- dependent monooxygenases in the horse and in other agricultural and laboratory species. Vet. J. 165(1), 53-64 (2003). (Pubitemid 38001823)
18. Mise M, Hashizume T, Komuro S. Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes. Drug Metab. Dispos. 36(9), 1903-1908 (2008).
19. Fink-Gremmels J. Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur. J. Pharmacol. 585(2-3), 502-509 (2008).
20. Kamimura H. Genetic polymorphism of cytochrome P450s in beagles: possible influence of CYP1A2 deficiency on toxicological evaluations. Arch. Toxicol. 80(11), 732-738 (2006). (Pubitemid 44817811)
21. Martignoni M, Groothuis GM. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2(6), 875-894 (2006). (Pubitemid 44911538)
22. Rawal S, Yip SS, Coulombe RA, Jr. Cloning, expression and functional characterization of cytochrome P450 3A37 from turkey liver with high aflatoxin B1 epoxidation activity. Chem. Res. Toxicol. 23(8), 1322-1329 (2010).
23. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of Phase I and Phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23(11), 1231-1241 (1995).
24. Komatsu T, Honda K, Kubota A, Kitazawa T, Hiraga T, Teraoka H. Molecular cloning and expression of cytochrome P450 2D6 in the livers of domestic cats. J. Vet. Med. Sci. 72(12), 1633-1636 (2010).
25. Shah SS, Sanda S, Regmi NL, Sasaki K, Shimoda M. Characterization of cytochrome P450-mediated drug metabolism in cats. J. Vet. Pharmacol. Ther. 30(5), 422-428 (2007). (Pubitemid 47366621)
26. Tanaka N, Shinkyo R, Sakaki T et al. Cytochrome P450 2E polymorphism in feline liver. Biochim. Biophys. Acta 1726(2), 194-205 (2005). (Pubitemid 41572259)
27. Tanaka N, Miyasho T, Shinkyo R, Sakaki T, Yokota H. cDNA cloning and characterization of feline CYP1A1 and CYP1A2. Life Sci. 79(26), 2463-2473 (2006). (Pubitemid 44750022)
28. van Beusekom CD, Schipper L, Fink- Gremmels J. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J. Vet. Pharmacol. Ther. 33(6), 519-527 (2010).
29. Lewis DF, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. 115(3), 175-199 (1998). (Pubitemid 28487023)
30. Fleischer S, Sharkey M, Mealey K, Ostrander EA, Martinez M. Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS. J. 10(1), 110-119 (2008).
31. Martinez M, Modric S. Patient variation in veterinary medicine: part I. Influence of altered physiological states. J. Vet. Pharmacol. Ther. 33(3), 213-226 (2010).
32. Modric S, Martinez M. Patient variation in veterinary medicine: part II. Influence of physiological variables. J. Vet. Pharmacol. Ther. 34(3), 209-223 (2011).
33. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem. J. 429(3), 435-449 (2010).
34. Jover R, Moya M, Gomez-Lechon MJ. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr. Drug Metab. 10(5), 508-519 (2009).
35. Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 85(4), 426-430 (2009).
36. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007). (Pubitemid 350116943)
37. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest. 1-12 (2010).
38. Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49(5), 295-310 (2010).
39. Watkins PB, Wrighton SA, Schuetz EG, Maurel P, Guzelian PS. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J. Biol. Chem. 261(14), 6264-6271 (1986). (Pubitemid 17204131)
40. Zhu BT. On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin. Drug Metab. Toxicol. 6(4), 483-494 (2010).
41. Dickins M. Induction of cytochromes P450. Curr. Top. Med. Chem. 4(16), 1745-1766 (2004). (Pubitemid 39654460)
42. Hakkola J, Pasanen M, Pelkonen O et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 18(2), 391-397 (1997). (Pubitemid 28132434)
43. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ. Expression and characterization of canine cytochrome P450 2D15. Arch. Biochem. Biophys. 357(1), 27-36 (1998). (Pubitemid 28402582)
44. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007).
45. Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum. Genomics 4(6), 402-405 (2010).
46. Giorgi MA, Di GG, Gonzalez CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin. Pharmacother. 11(14), 2391-2403 (2010).
47. Gladding P, Webster M, Zeng I et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1(6), 620-627 (2008).
48. Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet. Genomics 20(7), 463-465 (2010).
49. Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5(7), 895-931 (2004). (Pubitemid 39386756)
50. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41(2), 89-295 (2009).
51. Squires EJ, Lundstrom K. Relationship between cytochrome P450IIE1 in liver and levels of skatole and its metabolites in intact male pigs. J. Anim. Sci. 75(9), 2506-2511 (1997). (Pubitemid 127446731)
52. Moe M, Lien S, Aasmundstad T et al. Association between SNPs within candidate genes and compounds related to boar taint and reproduction. BMC Genet. 10, 32 (2009).
53. Bendixen E, Danielsen M, Larsen K, Bendixen C. Advances in porcine genomics and proteomics - a toolbox for developing the pig as a model organism for molecular biomedical research. Brief Funct. Genomics 9(3), 208-219 (2010).
54. van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J. Pharmacol. Toxicol. Methods 62(3), 184-195 (2010).
55. Ekser B, Rigotti P, Gridelli B, Cooper DK. Xenotransplantation of solid organs in the pig-to-primate model. Transpl. Immunol. 21(2), 87-92 (2009).
56. Witkamp R, Monshouwer M. Pharmacokinetic in vivo and in vitro in swine. Scand. J. Lab. Anim. Sci. 25(Suppl. 1), 45-56 (1998).
57. Kishida T, Muto S, Hayashi M et al. Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J. Toxicol. Sci. 33(4), 447-457 (2008).
58. Dacasto M, Eeckhoutte C, Capolongoa F et al. Effect of breed and gender on bovine liver cytochrome P450 3A (CYP3A) expression and inter-species comparison with other domestic ruminants. Vet. Res. 36(2), 179-190 (2005). (Pubitemid 40357642)
59. Depelchin BO, Bloden S, Michaux C, Ansay M. Effects of age, sex and breed on antipyrine disposition in calves. Res. Vet. Sci. 44(2), 135-139 (1988). (Pubitemid 18086494)
60. Goriya HV, Kalia A, Bhavsar SK, Joshi CG, Rank DN, Thaker AM. Comparative evaluation of phenobarbital-induced CYP3A and CYP2H1 gene expression by quantitative RT-PCR in Bantam, Bantamized White Leghorn and White Leghorn chicks. J. Vet. Sci. 6(4), 279-285 (2005).
61. Mise M, Yadera S, Matsuda M et al. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab. Dispos. 32(2), 240-245 (2004). (Pubitemid 38176942)
62. Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 14(11), 769-773 (2004). (Pubitemid 39552792)
63. Tenmizu D, Endo Y, Noguchi K, Kamimura H. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica 34(9), 835-846 (2004). (Pubitemid 39546272)
64. Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab. Dispos. 26(3), 278-283 (1998). (Pubitemid 28182406)
65. Paulson SK, Engel L, Reitz B et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab. Dispos. 27(10), 1133-1142 (1999). (Pubitemid 29463599)
66. de Zwart LL, Haenen HEMG, Versantvoort CHM, Sips AJAM. Pharmacokinetics of ingested xenobiotics in children: a comparison with adults. RIVM Report no. 623860011. National Institute for Public Health and the Environment, Bilthoven, The Netherlands (2002).
67. Clewell HJ, Teeguarden J, McDonald T et al. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32(5), 329-389 (2002). (Pubitemid 35191357)
68. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300(2), 355-360 (2002). (Pubitemid 34106223)
69. Tanaka E, Narisawa C, Nakamura H et al. Changes in the enzymatic activities of beagle liver during maturation as assessed both in vitro and in vivo. Xenobiotica 28(8), 795-802 (1998). (Pubitemid 28399046)
70. Virkel G, Carletti M, Cantiello M et al. Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa. J. Vet. Pharmacol. Ther. 33(3), 295-303 (2010).
71. Baillie TA. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19(7), 889-893 (2006). (Pubitemid 44092354)
72. Sun H, Scott DO. Structure-based drug metabolism predictions for drug design. Chem. Biol. Drug Des. 75(1), 3-17 (2010).
73. Smith DA, Obach RS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22(2), 267-279 (2009).
74. Zareba W. Drug induced QT prolongation. Cardiol. J. 14(6), 523-533 (2007). (Pubitemid 351278615)
75. Diaz GJ, Murcia HW, Cepeda SM. Cytochrome P450 enzymes involved in the metabolism of aflatoxin B1 in chickens and quail. Poult. Sci. 89(11), 2461-2469 (2010).
76. Szucs G, Tamasi V, Laczay P, Monostory K. Biochemical background of toxic interaction between tiamulin and monensin. Chem. Biol. Interact. 147(2), 151-161 (2004). (Pubitemid 38324543)
77. Cullen LK. Medetomidine sedation in dogs and cats: a review of its pharmacology, antagonism and dose. Br. Vet. J. 152(5), 519-535 (1996). (Pubitemid 26332280)
78. Baratta MT, Zaya MJ, White JA, Locuson CW. Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. J. Vet. Pharmacol. Ther. 33(1), 50-55 (2010).
79. Mills BM, Zaya MJ, Walters RR et al. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metab Dispos. 38(3), 396-404 (2010).
80. A Handbook of Bioanalysis and Drug Metabolism. Evans G (Ed.). CRC Press, NY, USA (2004)
81. Cytochrome P450 Protocols. Philips IR, Shephard EA (Eds.). Humana Press, NY, USA (2006)
82. Drug Metabolism in Drug Design and Development. Zhang D, Zhu M, Humphrey G (Eds). Wiley, NY, USA (2007)
83. Reddy M, Yang RS, Anderson ME, Clewell HJ. Physiologically Based Pharmacokinetic Modeling: Science and Applications. John Wiley & Sons, NY, USA (2011)
84. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
85. Zhao P, Zhang L, Grillo JA et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89(2), 259-267 (2010).
86. Ulveling D, Francastel C, Hube F. When one is better than two: RNA with dual functions. Biochimie 1-12 (2010).
87. The human cytochrome P450 (CYP) allele nomenclature committee www.cypalleles.ki.se
88. BLAST assembled RefSeq genomes www.ncbi.nlm.nih.gov/BLAST
89. Cytochrome P450 homepage http://drnelson.uthsc.edu/cytochromeP450.html
90. GenBank overview www.ncbi.nlm.nih.gov/Genbank/
91. Directory of P450-containing systems www.icgeb.org/p450srv/
92. Human (Homo sapiens) genome browser gateway http://genome.ucsc.edu/cgi- bin/hgGateway
93. P450 drug interaction table http://medicine.iupui.edu/clinpharm/ddis/ table.asp
94. Valnemulin: reintroduction medicated feed premix for swine dysentery and enzootic pneumonia www.octagon-services.co.uk/articles/econor.htm
95. Novartis completes extensive investigation of mysterious adverse drug reactions www.econor.com/newsroom/en-hp/back003. shtml
96. International Centre for Genetic Engineering and Biotechnology. Age-dependent changes in liver microsomal cytochrome P-450. www.icgeb.org/ p450srv/P450-ageing.html
97. Animal Pharmaceutics & Technology Focus Group www.aaps.org/inside/ focus-groups/Animal/index.asp
98. Sanofi-aventis. Plavix® prescribing information http://products. sanofi-aventis.us/plavix/plavix.htm